Searched for: subject:"Plasminogen%5C+Activator%5C+Inhibitor%5C+1"
(1 - 20 of 53)

Pages

document
Hawinkels, L.J.A.C. (author), Verspaget, H.W. (author), van der Reijden, J.J. (author), van der Zon, J.M. (author), Verheijen, J.H. (author), Hommes, D.W. (author), Lamers, C.B.H.W. (author), Sier, C.F.M. (author), TNO Kwaliteit van Leven (author)
Transforming growth factor-β1 (TGF-β1), a cytokine involved in various stages of cancer, is produced as a latent complex and requires processing to become active. We have determined total and active TGF-β1 levels in homogenates of colorectal neoplasia. In contrast to total TGF-β levels, showing a stepwise increase in the mucosa-adenoma-carcinoma...
article 2009
document
Hellebrekers, B.W.J. (author), Trimbos-Kemper, T.C.M. (author), Boesten, L. (author), Jansen, F.W. (author), Kolkman, W. (author), Trimbos, J.B. (author), Press, R.R. (author), van Poelgeest, M.I.E. (author), Emeis, S.J. (author), Kooistra, T. (author), TNO Kwaliteit van Leven (author)
Objective: To identify predictors of postsurgical adhesion formation in peritoneal fluid and plasma, and assess efficacy and safety of reteplase (recombinant plasminogen activator [r-PA]). Design: Prospective randomized study. Setting: University Medical Center. Patient(s): Twenty-six abdominal myomectomy patients with early second-look...
article 2009
document
Geert Heidema, A. (author), Thissen, U. (author), Boer, J.M.A. (author), Bouwman, F.G. (author), Feskens, E.J.M. (author), Mariman, E.C.M. (author), TNO Kwaliteit van Leven (author)
In this study, we applied the multivariate statistical tool Partial Least Squares (PLS) to analyze the relative importance of 83 plasma proteins in relation to coronary heart disease (CHD) mortality and the intermediate end points body mass index, HDL-cholesterol and total cholesterol. From a Dutch monitoring project for cardiovascular disease...
article 2009
document
Rijken, D.C. (author), Hoegee-de Nobel, E. (author), Jie, A.F.H. (author), Atsma, D.E. (author), Schalij, M.J. (author), Nieuwenhuizen, W. (author), TNO Kwaliteit van Leven (author)
Background: The development of global tests for the fibrinolytic capacity in blood is hampered by the low base-line fibrinolytic activity in blood, by the involvement of both plasmatic components and blood cells in the fibrinolytic system and by the loss of fibrinolytic activity as a result of the action of plasminogen activator inhibitor-1 (PAI...
article 2008
document
Alizadeh Dehnavi, R. (author), Beishuizen, E.D. (author), van de Ree, M.A. (author), Le Cessie, S. (author), Huisman, M.V. (author), Kluft, C. (author), Princen, H.M.G. (author), Tamsma, J.T. (author), TNO Kwaliteit van Leven (author)
Background: The burden of cardiovascular disease in diabetes mellitus type 2 (DM2) patients is variable. We hypothesize that metabolic syndrome (MS) and low-grade systemic inflammation modify the extent of atherosclerosis in DM2. Methods: Vascular phenotype was determined using the following endothelium-related, hemostatic, and sonographic...
article 2008
document
Hu, L. (author), Bovenschen, N. (author), Havekes, L.M. (author), van Vlijmen, B.J.M. (author), Tamsma, J.T. (author), TNO Kwaliteit van Leven (author)
article 2007
document
Pons, D. (author), Monraats, P.S. (author), de Maat, M.P.M. (author), Pires, N.M.M. (author), Quax, P.H.A. (author), van Vlijmen, B.J.M. (author), Rosendaal, F.R. (author), Zwinderman, A.H. (author), Doevendans, P.A.F.M. (author), Waltenberger, J. (author), de Winter, R.J. (author), Tio, R.A. (author), Frants, R.R. (author), van der Laarse, A. (author), van der Wall, E.E. (author), Jukema, J.W. (author), TNO Kwaliteit van Leven (author)
Since activation of the haemostatic system is an important feature of the wound healing response triggered by arterial injury, variations in genes involved in thrombus formation may play a role in restenosis after percutaneous coronary interventions (PCI). Therefore, our aim was to examine the relationship between polymorphisms that are known to...
article 2007
document
Verschuren, L. (author), Kleemann, R. (author), Offerman, E.H. (author), Szalai, A.J. (author), Emeis, S.J. (author), Princen, H.M.G. (author), Kooistra, T. (author), TNO Kwaliteit van Leven (author)
Objective - To evaluate whether low-dose atorvastatin suppresses atherosclerotic lesion progression and inflammation in apolipoprotein E*3 (apoE*3)-Leiden mice beyond its cholesterol-lowering effect. Methods and Results - ApoE*3-Leiden mice were fed a high-cholesterol (HC) diet until mild atherosclerotic lesions had formed. Subsequently, HC diet...
article 2005
document
de Maat, M.P.M. (author), Jansen, M.W.J.C. (author), Hille, E.T.M. (author), Vos, H. (author), Bloemenkamp, K.W.M. (author), Buitendijk, S.E. (author), Helmerhorst, F.M. (author), Wladimiroff, J.W. (author), Bertina, R.M. (author), de Groot, C.J.M. (author), TNO Preventie en Gezondheid (author)
Recently, it has been proposed that abnormalities in coagulation and fibrinolysis contribute to the development of preeclampsia by increasing the thrombotic tendency. This hypothesis was tested in women who have had preeclampsia (cases) compared with matched controls. Polymorphisms in the thrombophilia genes {plasminogen activator inhibitor type...
article 2004
document
Schulter, V. (author), Koolwijk, P. (author), Peters, E. (author), Frank, S. (author), Hrzenjak, A. (author), Graier, W.F. (author), van Hinsbergh, V.W.M. (author), Kostner, G.M. (author), Gaubius Instituut TNO (author)
Angiostatin, which consists of the kringle I-IV domains of plasminogen and which is secreted into urine, is an efficient inhibitor of angiogenesis and tumor growth. Because N-terminal apolipoprotein(a) [apo(a)] fragments, which also contain several types of kringle IV domains, are found in urine as well, we evaluated the potential angiostatic...
article 2001
document
Riese, H. (author), Houtman, I.L.D. (author), Doornen, L.J.P. (author), de Geus, E.J.C. (author)
This study examined the possible effects of job demands, decision latitude, and job-related social support on risk indicators for cardiovascular disease (CVD) in 165 female nurses. Job strain was measured with the Job Content Questionnaire; CVD risk was measured with insulin, total cholesterol, triglyceride (TG), high-density lipoprotein...
article 2000
document
Kockx, M. (author), Leenen, R. (author), Seidell, J. (author), Princen, H.M.G. (author), Kooistra, T. (author), Gaubius instituut TNO (author)
This study was aimed at evaluating the relationship between visceral fat accumulation and plasma plasminogen activator inhibitor-1 (PAI-1) levels in healthy, obese men and women undergoing weight loss therapy. The subjects, 25 men and 25 premenopausal women, aged between 26 and 49 years, with an initial body mass index between 28 and 38 kg/m2,...
article 1999
document
Myrup, B. (author), Rossing, P. (author), Jensen, T. (author), Gram, J. (author), Kluft, C. (author), Jespersen, J. (author), Gaubius instituut TNO (author)
Objective: To investigate protein concentration changes during venous occlusion of proteins with reported affinity for extracellular matrix (plasminogen activator inhibitor type 1, antithrombin III, fibronectin and von Willebrand factor) in comparison with proteins with no reported affinity (albumin, tissue-type plasminogen activator,...
article 1999
document
Heijmans, B.T. (author), Westendorp, R.G.J. (author), Knook, D.L. (author), Kluft, C. (author), Slagboom, P.E. (author), Gaubius instituut TNO (author)
OBJECTIVES: We studied the contribution of putative risk genotypes at the angiotensin I-converting enzyme inhibitor (ACE D/D) and plasminogen activator inhibitor-1 (PAI-1 4G/4G) loci to all-cause and cardiovascular mortality in a population-based cohort. BACKGROUND: The ACE D/D and PAI-1 4G/4G genotypes have been consistently associated with...
article 1999
document
Larsson, P.T. (author), Wallén, N.H. (author), Wiman, B. (author), Dooijewaard, G. (author), Gaubius instituut TNO (author)
Objective: To study the influence of α- and β-adrenoceptor stimulation in vivo on fibrinolysis in healthy male volunteers. Design: Infusions were given in a single blind fashion and in a randomized order if placebo infusions were included. Setting: University Department (Karolinska Hospital). Subjects: Thirty-four healthy, non-smoking male...
article 1999
document
Sitter, T. (author), Toet, K. (author), Quax, P. (author), Kooistra, T. (author), Gaubius instituut TNO (author)
Background. Human mesothelial cells (HMCs) have an important role in maintaining an adequately functioning fibrinolytic system in the peritoneal cavity by secreting the fibrinolytic enzymes tissue-type and urokinase-type plasminogen activator (t-PA and u-PA), as well as a specific PA inhibitor, PA inhibitor type 1 (PAI-1). In this study, we...
article 1999
document
Arts, J. (author), Grimbergen, J. (author), Toet, K. (author), Kooistra, T. (author), Gaubius instituut TNO (author)
We have characterized the regulation of plasminogen activator inhibitor- 1 (PAI-1) gene expression by phorbol 12-myristate 13-acetate (PMA), serum, and interleukin-1α (IL-1α) in the human hepatoma cell line HepG2. PMA, serum, and IL-1α induced a rapid and transient 28-fold (PMA), 9-fold (serum), and 23-fold (IL-1α) increase in PAI-1 mRNA,...
article 1999
document
Kockx, M. (author), Princen, H.M.G. (author), Kooistra, T. (author), Gaubius Instituut TNO (author)
Fibrates are used to lower plasma triglycerides and cholesterol levels in hyperlipidemic patients. In addition, fibrates have been found to alter the plasma concentrations of fibrinogen, plasminogen activator inhibitor-1 (PAI-1) and apolipoprotein A-I (apo A-I). We have investigated the in vitro effects of fibrates on fibrinogen, PAI-1 and apo A...
article 1998
document
Rosén, S. (author), Wejkum, L. (author), Billing-Claeson, S. (author), Ghosh, R. (author), Grdic, K. (author), Chmielewska, J. (author), Meijer, P. (author), Kluft, C. (author), Tengborn, L. (author), Conkie, J. (author), Walker, I. (author), Gaubius Instituut TNO (author)
A chromogenic bioimmunoassay method for determination of t-PA activities has been evaluated on plasmas from healthy individuals and from thromboembolic patients. The assay consists of an initial binding and washing step, whereby plasma t-PA is bound to a specific monoclonal t-PA antibody, which is coated on to microplate wells, followed by a...
article 1998
document
Weststrate, J.A. (author), van het Hof, K.H. (author), van den Berg, H. (author), te Velthuis-te-Wierik, E.J.M. (author), de Graaf, C. (author), Zimmermanns, N.J.H. (author), Westerterp, K.R. (author), Westerterp-Plantenga, M.S. (author), van de Verboeket-Venne, W.P.H.G. (author), Centraal Instituut voor Voedingsonderzoek TNO (author)
Objectives: To compare the effects of free access to reduced fat products or their full fat equivalents on fat and energy intake, body weight, plasma lipids and fat-soluble antioxidants concentrations and haemostasis variables. Design: A multicentre open randomised controlled trial in which intervention and control groups were followed in...
article 1998
Searched for: subject:"Plasminogen%5C+Activator%5C+Inhibitor%5C+1"
(1 - 20 of 53)

Pages